Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma

Standard therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) is multi-targeted kinase inhibitors (m-TKIs), represented by sorafenib and lenvatinib. One of the main target molecules of m-TKIs is vascular endothelial growth factor receptor (VEGF-R). m-TKIs are known to...

Full description

Bibliographic Details
Main Authors: Yasuko Hyogo, Naomi Kiyota, Naoki Otsuki, Shunsuke Goto, Yoshinori Imamura, Naoko Chayahara, Masanori Toyoda, Ken-ichi Nibu, Toshiki Hyodo, Shigeo Hara, Hiroo Masuoka, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
Format: Article
Language:English
Published: Karger Publishers 2018-11-01
Series:Case Reports in Oncology
Subjects:
Lenvatinib
Thrombotic microangiopathy
Proteinuria
Radioactive iodine- refractory differentiated thyroid cancer
Online Access:https://www.karger.com/Article/FullText/494080

Internet

https://www.karger.com/Article/FullText/494080

Similar Items